SLC7A11 and ovarian carcinoma: In addition to the classical SLC7A11 inhibitors (e.g., erastin and sorafenib), subsequent drug screening also found that regorafenib can inhibit SLC7A11, thereby enhancing the anticancer activity of PACMA31 in OVCAR-8 (human ovarian cancer cell line) cells in vitro and in vivo.